<DOC>
	<DOCNO>NCT01254019</DOCNO>
	<brief_summary>The purpose study determine whether GSK2402968 effective treatment ambulant boy Duchenne muscular dystrophy result mutation think correct exon 51 skipping .</brief_summary>
	<brief_title>A Clinical Study Assess Efficacy Safety GSK2402968 Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Ambulant subject Duchenne muscular dystrophy result mutation/deletion within DMD gene , confirm stateoftheart DNA diagnostic technique cover DMD gene exon , include limited MLPA ( Multiplex Ligationdependent Probe Amplification ) , CGH ( Comparative Genomic Hybridisation ) , SCAIP ( Single Condition Amplification/Internal Primer ) HRMCA ( HighResolution Melting Curve Analysis ) , correctable GSK2402968induced DMD exon 51 skipping . Males , age least 5 year , life expectancy least 1 year Able complete 6MWD test minimal distance least 75m predrug visit . In addition , result 6MWD must within 20 % predrug visit Receiving glucocorticoid minimum 6 month immediately prior screening , significant change total daily dosage dose regimen minimum 3 month immediately prior screen reasonable expectation total daily dosage dose regimen change significantly duration study QTc &lt; 450msec ( base single average QTc value triplicate ECGs obtain brief recording period ) , &lt; 480 msec subject Bundle Branch Block . Note : QTc may either QTcB QTcF , machine read manual overread . Subjects , appropriate , must willing use adequate contraception ( condoms abstinence ) duration study least 5 month last dose study drug . Willing able comply protocol requirement procedure , Able give inform assent and/or consent writing sign subject and/or parent ( ) /legal guardian ( accord local regulation ) . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Any additional missing exon DMD treat GSK2402968 Current history liver renal disease impairment Acute illness within 4 week first anticipate administration study medication may interfere study assessment Use anticoagulant , antithrombotics antiplatelet agent , previous treatment investigational drug , within 6 month first administration study medication ; idebenone form Coenzyme Q10 within 1 month first administration study medication . Current anticipated participation investigational clinical study Positive hepatitis B surface antigen , hepatitis C antibody test ( verified via RIBA PCA test ) , human immunodeficiency virus ( HIV ) test screening , Symptomatic cardiomyopathy . If subject leave ventricular ejection fraction &lt; 45 % Screening , investigator discus inclusion subject study medical monitor , Children Care . The definition Child Care child place control protection agency , organisation , institution entity court , government government body , act accordance power confer law regulation . The definition child care include child cared foster parent live care home institution , provide arrangement fall within definition . The definition child care include child adopt appointed legal guardian .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>968</keyword>
	<keyword>GSK</keyword>
	<keyword>Duchenne</keyword>
</DOC>